LONDON, January 18, 2022 – Materia (“Materia” or the “Company”) is pleased to share an update on the company’s recent operational performance, including the success of its recently launched brand into the European market.
Read moreMateria Malta Begins First Sales of Medical Cannabis in Europe
LONDON, December 16th, 2021 – Materia today announces that its wholly-owned subsidiary Materia Malta Operating Ltd. (“Materia Malta” or “the “Company”) has commenced sales of the first medical cannabis flower produced at its EU GMP certified manufacturing site.
Read moreMateria Receives Commercial Production Licence for Malta Facility
LONDON, September 14th, 2021 — Materia today announces that its wholly-owned subsidiary Materia Malta Operating Ltd. (“Materia Malta” or the “Company”) has received its Licence for the Production of Cannabis for Medicinal and Research Purposes (the “Licence”) from the Malta Medicines Authority.
Read moreMateria Becomes Distribution Partner of Eurox Pharma for German-Produced Medical Cannabis Extracts
LONDON, August 17th, 2021 — Materia, a leading processor and distributor of medical cannabis and CBD wellness products across Europe, is pleased to announce that its wholly-owned subsidiary Materia Deutschland GmbH (“Materia Deutschland”), has entered into an agreement with German medical cannabis manufacturer Eurox Pharma GmbH (“Eurox Pharma”), becoming one of Eurox Pharma’s selected distribution partners for its medical cannabis extracts.
Read moreMateria Announces Receipt of EU-GMP Certification in Malta
LONDON, May 13, 2021 — Materia, a medical cannabis and wellness company focused on the European market, today announces that its wholly-owned subsidiary Materia Malta Operating Ltd. (“Materia Malta” or the “Company”) has received its European Union Good Manufacturing Practices (“EU GMP”) certification from the Malta Medicines Authority.
Read moreMateria and Saxonia Diagnostics Announce Exclusive Partnership for Distribution of Pharmacy Cannabis Testing Products
LONDON, May 5th, 2021 — Materia, a medical cannabis and wellness company focused on the European market, today announced that its wholly-owned subsidiary Materia Deutschland GmbH (“Materia Deutschland”) has entered into a partnership with German diagnostics company Saxonia Diagnostics GmbH (“Saxonia Diagnostics”) for the exclusive distribution of its branded cannabis testing products across Germany.
Read moreMateria Announces Strategic Portfolio Expansion
LONDON, Feb 23, 2021 /CNW/ — Materia, a medical cannabis and wellness company focused on the European market, is pleased to announce that its wholly-owned subsidiary Materia Deutschland GmbH (“Materia Deutschland”), is expanding its portfolio of medical cannabis products being offered to pharmacies across Germany.
Materia Attains EU-GMP Certificate and Manufacturing and Import Licence in Germany
LONDON, Jan 28, 2021 /CNW/ — Materia, a medical cannabis and wellness company focused on the European market, is pleased to announce that its wholly-owned subsidiary Materia Deutschland GmbH (“Materia Deutschland” or the “Company”), has received its European Union Good Manufacturing Practices (“EU-GMP”) certificate as well as its manufacturing and import (“MIA”) licence. Following successful inspections by the local authorities, the Company was adjudged to comply with the high standard of production guidelines required to import, conduct manufacturing activities and batch release medical cannabis products.
Materia and Pure Ratios to Launch Award-Winning CBD Topicals into the UK Market
LONDON, July 9, 2020 /CNW/ – Materia (“Materia” or the “Company”), a medical cannabis and CBD wellness company focused on the European market, today announced an agreement with Pure Ratios Holdings Inc.(“Pure Ratios”), an award-winning CBD topical manufacturer and subsidiary of 4Front Ventures Corp(CSE:FFNT, OTCQX:FFNTF), to distribute and market its products across Europe.
Read moreMateria tritt mit der Übernahme eines lizenzierten Importeurs und Distributeur für medizinisches Cannabis in den deutschen Markt ein
Hamburg, 14. Mai 2020 – Materia („Materia“ oder das „Unternehmen“), ein Unternehmen für medizinisches Cannabis und CBD Produkte mit Schwerpunkt auf dem europäischen Markt, gibt bekannt, dass es 100% der Gesellschaftsanteile der Cannaktiv GmbH („Cannaktiv“) erworben hat. Cannaktiv wurde im Juni 2018 in Hamburg gegründet und hält alle erforderlichen Erlaubnisse und Zulassungen für den Import und Vertrieb von medizinischem Cannabis an Großhändler und Apotheken in Deutschland. Diese sind: